- Published on
Early progress on accelerating drug development with Claude
- Authors
- Name
- DeepHorus
Anthropic’s life sciences team has partnered with six organizations to accelerate drug development and has launched internal discovery programs. The partners are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group. Anthropic is also pursuing its own programs, including rare childhood muscular dystrophies, with Claude handling much scientific and operational work.
Drug development has bottlenecks across target identification, molecule design, manufacturing, regulatory filings, and clinical trials. Anthropic argues that AI must be embedded in real programs across diseases and stages rather than treated as a single fix. The partnerships are meant to reveal Claude’s strengths and limitations.
Generate Biomedicines used Claude Code to redesign part of CAR T-cell therapy for solid tumors. Six scientists proposed new genetic-instruction designs; one was about 70% shorter than standard. Lab tests showed roughly 10 times more receptors, more efficient tumor-cell killing, and longer immune-cell activity.
Divergence Labs is applying the approach to food allergies, which involve the molecule IgE. Anthropic said the work helps it identify model improvements, which it has already prioritized. Such projects can also serve as case studies for biotechnology firms seeking to integrate Claude.
The programs serve three goals: improving Anthropic’s models, demonstrating use cases for life sciences, and potentially producing new medicines. If positive trajectories continue, some may yield treatments for food allergies, rare childhood diseases, and several cancers. Anthropic plans to scale the work substantially.
The company said no single problem explains drug-development delays. It will need deeper partnerships with more biotechnology firms to realize AI’s medical potential. Early results remain preliminary, but Anthropic is optimistic about direct impact.
